Adjunctive topiramate in ultradian cycling bipolar disorder: case report with 3-year follow-up.
A patient with a treatment-refractory bipolar disorder with ultradian cycling responded to adjunctive topiramate. Response was maintained during 3-year follow-up.
Karama
Sherif
S
Douglas Hospital Research Center, McGill University, 6875 LaSalle Blvd., Verdun, Quebec, Canada H4H 1R3.
Lal
Samarthji
S
D000204:Activity Cycles / Q000187:drug effects*; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage; D001590:Benztropine / Q000008:administration & dosage; D001714:Bipolar Disorder / Q000188:drug therapy*; D004351:Drug Resistance / Q000502:physiology; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D018020:Lithium Compounds / Q000008:administration & dosage; D008152:Loxapine / Q000008:administration & dosage; D010276:Parasympatholytics / Q000008:administration & dosage; D000077236:Topiramate; D014635:Valproic Acid / Q000008:administration & dosage
D000927:Anticonvulsants; D018692:Antimanic Agents; D014150:Antipsychotic Agents; D018020:Lithium Compounds; D010276:Parasympatholytics; D000077236:Topiramate; D001590:Benztropine; D005632:Fructose; D014635:Valproic Acid; D008152:Loxapine